by Tanya B. Dorff, MD; Robert Dreicer, MD, MS, MACP, FASCO; and Neal D. Shore, MD, FACS
With multiple treatments now available for advanced prostate cancer, there are many options for the sequencing of therapies. Our featured experts e......READ MORE
by Tanya B. Dorff, MD; Robert Dreicer, MD, MS, MACP, FASCO; and Neal D. Shore, MD, FACS
Molecular and genomic tests have the potential to add key prognostic data to the assessment of earlier-stage prostate cancer. Ongoing trials seek t......READ MORE
by Tanya B. Dorff, MD; Robert Dreicer, MD, MS, MACP, FASCO; and Neal D. Shore, MD, FACS
Our featured experts highlight opportunities to optimize care, focusing on the treatment of metastatic castration-sensitive prostate cancer (mCSPC)......READ MORE
by Tanya B. Dorff, MD; Robert Dreicer, MD, MS, MACP, FASCO; and Neal D. Shore, MD, FACS
At least 6 mechanistically distinct categories of therapy are now available for metastatic castration-resistant prostate cancer (mCRPC), prompting ......READ MORE
by Peter R. Carroll, MD, MPH; Daniel J. George, MD; and Oliver Sartor, MD
Genomic and molecular heterogeneity is a hallmark of metastatic castration-resistant prostate cancer (mCRPC). As both genomic testing and novel sys......READ MORE
